NOVARTIS MULTIDISCIPLINARY MEETING

Meeting Objective: To educate and update GPs about management and treatment of Heart Failure and Rheumatology



Tuesday, 23rd August 2022 DATE:

7:00pm - 8:30pm TIME:

VENUE: The Balcony Restaurant

287 Flinders Street Townsville QLD 4810 SPEAKERS:

Dr Dharmesh Anand- Cardiologist

Dr Ildiko Lujberene Telegdy - Rheumatologist

TIME	AGENDA	SPEAKER
6:30 PM	Registration	
6:55 PM	Welcome, Meeting Objectives and Introduction	Novartis
7:00 PM	Why you should act early to reduce the risk of sudden death in your patients with HFrEF	Dr Dharmesh Anand
7:30 PM	Q&A	Dr Dharmesh Anand
7:45 PM	"Is Inflammation hiding in plain sight?" - an update in Rheumatolgy	Dr Ildiko Lujberene Telegdy
8:15 PM	Q&A	Dr Ildiko Lujberene Telegdy
8:30 PM	Meeting Close	

RSVP by Friday, 19th August 2022

To register your attendance, please see details overleaf.





NOVARTIS MULTIDISCIPLINARY MEETING



TO REGISTER YOUR ATTENDANCE,
SCAN THE QR CODE
OR GO ONLINE: https://evt.to/auusgsmaw



FOR ANY QUESTIONS REGARDING THE MEETING, PLEASE CONTACT:

Jayne Owen on 0449 564 635

Privacy Information

Your personal information will be processed in accordance with the Novartis Privacy Policy at https://www.novartis.com.au/privacy-policy.

Your information, including any information forwarded to the Novartis Patient Safety department, may be processed and stored on servers located in jurisdictions outside of the country in which it was collected.

You consent to Novartis using your personal information to communicate with you about Novartis products and services, and to invite you to, or arrange your participation in, activities managed by Novartis. You are not obliged to provide personal information, however if you do not, you may not be able to participate fully in activities managed by Novartis. You have the right to access, update or correct your personal information or decline to receive marketing communications from Novartis. To find out how, please refer to the Novartis Privacy Policy.

Novartis is committed to Patient Safety. In accordance with regulatory obligations for reporting safety information Novartis processes reports of adverse events experienced by patients on Novartis products when identified by a Novartis representative (or by a third party acting on behalf of Novartis). Novartis Patient Safety may contact you or your healthcare professional in order to collect further information on the adverse event. This information may be shared with health authorities or other pharmaceutical companies with whom Novartis has a license agreement, and third parties we work with for the purpose of safety reporting.

In accordance with the Code of Conduct for the prescription medicine industry in Australia, any costs (for example travel or meals) incurred by a partner/spouse, guest or family member travelling with a healthcare professional must not be paid for or subsidised by the company.

Novartis Pharmaceuticals Australia Pty Limited. ABN 18 004 244 160. 54 Waterloo Road, Macquarie Park NSW 2113. Ph (02) 9805 3555. June 2022. AU-21052.

